Standard of care for children with newly diagnosed B‐cell ALL

CANCERagent used to prevent breast cancer and improve bone density, stimulates the growth of breast and endometrial cancer in mice previously treated with tamoxifen. 2 Using this knowledge, she developed and conducted translational breast cancer trials at Emory University and was recruited as the chief of hematology and medical oncology at the Georgia Cancer Center for Excellence at Grady Memorial Hospital. 3 During this time, she became interested in another resistant breast cancer, TNBC, which occurs more frequently in Black women.Her laboratory work showed the role of plasticity in the progression of mesenchymal TNBC. 4 She also became interested in the role of androgen receptors (ARs) in TNBC and demonstrated crosstalk between the AR and the mesenchymal pathways. 5During her time at the University of Wisconsin, her laboratory showed that the combination of AR and CDK4/6 inhibition is effective in AR-positive TNBC, and this led to the development of an ongoing clinical trial.Currently, she is the lead researcher for two active clinical trials.One is an open-label, phase 2 trial examining the efficacy of preoperative neratinib and endocrine therapy with trastuzumab in women with ER-positive and human epidermal growth factor receptor 2 (HER2)-positive breast cancers.The other is an open-label, single-arm, phase 2 trial of ribociclib combined with bicalutamide for advanced AR-positive TNBC. Clinician, educator, and mentorAs the associate director of education and mentoring at the